Brief: aTyr Pharma Announces Topline Results From Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
15/09/2025 12:36
Sept 15 (Reuters) - aTyr Pharma Inc ATYR.O: ATYR PHARMA ANNOUNCES TOPLINE RESULTS FROM PHASE 3 EFZO-FIT™ STUDY OF EFZOFITIMOD IN PULMONARY SARCOIDOSIS ATYR PHARMA INC - STUDY DID NOT MEET PRIMARY ENDPOINT IN OCS DOSE CHANGE ATYR PHARMA INC - COMPANY TO ENGAGE WITH FDA ON EFZOFITIMOD PATH FORWARD Source text: ID:nGNX4LhSlG Further company coverage: ATYR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan